Community Hospital Anderson
- Type
- Teaching hospital
- Where
- Anderson, IN
- Medicare CCN
- 150113
- Received
- $234,392 in 162 records, 2020 ($1,633 general, $232,759 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 4 | $1,633 |
| 2020 | Research payment | 158 | $232,759 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novo Nordisk AS | 128 | $116,097 | 2020 |
| AstraZeneca Pharmaceuticals LP | 2 | $45,503 | 2020 |
| PFIZER INC. | 14 | $41,090 | 2020 |
| UCB SA | 2 | $11,182 | 2020 |
| Novartis Pharmaceuticals Corporation | 2 | $9,151 | 2020 |
| Celgene Corporation | 1 | $6,000 | 2020 |
| Esperion Therapeutics, Inc. | 7 | $3,091 | 2020 |
| Stryker Corporation | 3 | $1,593 | 2020 |
| Eli Lilly and Company | 2 | $643 | 2020 |
| Siemens Medical Solutions USA, Inc. | 1 | $40 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 158 | $232,759 |
| Gift | 3 | $1,593 |
| Charitable Contribution | 1 | $40 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $6,233 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $40 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-22 | Novo Nordisk AS | $10,308 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $200 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-12-21 | Esperion Therapeutics, Inc. | $601 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-21 | Esperion Therapeutics, Inc. | $361 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-21 | Esperion Therapeutics, Inc. | $283 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-18 | Novo Nordisk AS | $131 | Research payment | In-kind items and services | Wegovy Drug, Diabetes | EX9536-4388 | 2020 |
| 2020-12-10 | Novo Nordisk AS | $200 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-11-30 | Novo Nordisk AS | $6,137 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-11-23 | Esperion Therapeutics, Inc. | $361 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-19 | Eli Lilly and Company | $48 | Research payment | In-kind items and services | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2020 | |
| 2020-10-29 | Novo Nordisk AS | $3,955 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-10-29 | Novo Nordisk AS | $1,159 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-10-08 | UCB SA | $4,362 | Research payment | Cash or cash equivalent | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of padsevonil a | 2020 | |
| 2020-10-01 | PFIZER INC. | $15,922 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-10-01 | PFIZER INC. | $837 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-10-01 | Novo Nordisk AS | $64 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-09-24 | Novo Nordisk AS | $10,437 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-09-24 | Novo Nordisk AS | $800 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-09-24 | Esperion Therapeutics, Inc. | $601 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-24 | Esperion Therapeutics, Inc. | $601 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-24 | Esperion Therapeutics, Inc. | $283 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-24 | Novo Nordisk AS | $262 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-08-27 | Novo Nordisk AS | $5,129 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-08-27 | Novo Nordisk AS | $400 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $360 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $79 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-25 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-08-20 | PFIZER INC. | $22 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2020 |
| 2020-07-30 | Novo Nordisk AS | $6,805 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-07-02 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2020 |
| 2020-06-25 | Novo Nordisk AS | $200 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-06-23 | Novo Nordisk AS | $8,901 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-06-18 | PFIZER INC. | $436 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2020 |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $28 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-18 | Novo Nordisk AS | $12 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-06-04 | PFIZER INC. | $11,237 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-06-01 | Stryker Corporation | $361 | Gift | In-kind items and services | STRYKER AIR PUMP Device, PATIENT HANDLING - PH | 2020 | |
| 2020-06-01 | Stryker Corporation | $361 | Gift | In-kind items and services | STRYKER AIR PUMP Device, PATIENT HANDLING - PH | 2020 | |
| 2020-05-28 | Novo Nordisk AS | $10,592 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-05-28 | Novo Nordisk AS | $400 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-05-21 | PFIZER INC. | $2,682 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2020 |
| 2020-04-30 | Novo Nordisk AS | $5,091 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-04-15 | Stryker Corporation | $870 | Gift | In-kind items and services | PRIME TC TRANSPORT CHAIR Device, PATIENT HANDLING - PH | 2020 | |
| 2020-03-24 | Novo Nordisk AS | $16,775 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-03-24 | Novo Nordisk AS | $200 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-03-18 | Novartis Pharmaceuticals Corporation | $4,050 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | OBSERVATIONAL REGISTRY OF TREATMENT PATTERNS IN US HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION | 2020 |
| 2020-03-09 | UCB SA | $6,819 | Research payment | Cash or cash equivalent | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of padsevonil a | 2020 | |
| 2020-02-27 | Novo Nordisk AS | $13,513 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-02-27 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-02-20 | PFIZER INC. | $525 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2020 |
| 2020-02-20 | PFIZER INC. | $525 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2020 |
| 2020-02-20 | PFIZER INC. | $525 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2020 |
| 2020-02-20 | PFIZER INC. | $483 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2020 |
| 2020-02-12 | Novo Nordisk AS | $183 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-02-11 | Celgene Corporation | $6,000 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Celgene - Connect MM | 2020 |
| 2020-02-06 | PFIZER INC. | $6,196 | Research payment | Cash or cash equivalent | STEGLATRO Drug, CARDIOVASCULAR | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFI | 2020 |
| 2020-01-31 | Novo Nordisk AS | $129 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $16 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-28 | Novo Nordisk AS | $10,202 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-01-28 | Eli Lilly and Company | $595 | Research payment | In-kind items and services | A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN | 2020 | |
| 2020-01-28 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-13 | Novo Nordisk AS | $449 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-10 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-08 | Novartis Pharmaceuticals Corporation | $5,101 | Research payment | Cash or cash equivalent | GILENYA Drug, NEUROSCIENCE | LONG TERM PROSPECTIVE MULTINATIONAL PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY ST | 2020 |
| 2020-01-08 | PFIZER INC. | $463 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-01-08 | PFIZER INC. | $231 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-01-07 | Novo Nordisk AS | $29 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-06 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2020 | |
| 2020-01-02 | AstraZeneca Pharmaceuticals LP | $39,269 | Research payment | Cash or cash equivalent | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Anderson, IN, county Madison County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Anderson, IN | County Madison County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 55,367 | 131,900 | 6,851,073 |
| Population, 2020 census P1 | 54,788 | 130,129 | 6,785,528 |
| Median age B01002 | 38.9 | 40.9 | 38.1 |
| Under 18 B01001 | 20.9% | 21.4% | 23.3% |
| 65 and over B01001 | 19.3% | 18.8% | 16.8% |
| Households B11001 | 24,218 | 53,429 | 2,716,009 |
| Foreign born B05002 | 2.8% | 2.1% | 6.3% |
| Median household income B19013 | $46,909 | $63,037 | $71,957 |
| Median family income B19113 | $63,417 | $78,904 | $90,767 |
| Per capita income B19301 | $28,833 | $33,926 | $38,351 |
| Poverty rate B17001 | 21.0% | 13.4% | 12.3% |
| Unemployment rate B23025 | 7.3% | 5.9% | 4.3% |
| Civilian labor force B23025 | 26,008 | 64,421 | 3,472,016 |
| Mean commute (minutes) B08013 | 24.7 | 26.3 | 24.1 |
| Bachelor's degree or higher B15003 | 15.7% | 20.5% | 29.5% |
| Housing units B25001 | 27,483 | 59,301 | 2,976,568 |
| Owner-occupied B25003 | 55.5% | 70.2% | 70.6% |
| Renters B25003 | 44.5% | 29.8% | 29.4% |
| Median home value B25077 | $119,000 | $161,300 | $218,200 |
| Median gross rent B25064 | $925 | $939 | $1,062 |
| White, not Hispanic B03002 | 72.5% | 82.0% | 75.4% |
| Black B03002 | 11.6% | 6.1% | 9.1% |
| Hispanic or Latino B03002 | 8.1% | 5.4% | 8.6% |
| Asian B03002 | 0.6% | 0.7% | 2.6% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Anderson, IN.
Comments